US 12,213,996 B2
Methods of treating optic nerve diseases using neural progenitor cell growth factors
Steven Lance Bernstein, Chevy Chase, MD (US); Candace L. Kerr, Westminster, MD (US); and Sally Temple Stern, Slingerlands, NY (US)
Assigned to UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US); and REGENERATIVE RESEARCH FOUNDATION, Rensselaer, NY (US)
Appl. No. 16/966,204
Filed by University of Maryland, Baltimore, Baltimore, MD (US); REGENERATIVE RESEARCH FOUNDATION, Rensselaer, NY (US); Steven Lance Bernstein, Chevy Chase, MD (US); Candace L. Kerr, Westminster, MD (US); and Sally Temple Stern, Slingerlands, NY (US)
PCT Filed Feb. 1, 2019, PCT No. PCT/US2019/016303
§ 371(c)(1), (2) Date Jul. 30, 2020,
PCT Pub. No. WO2019/152812, PCT Pub. Date Aug. 8, 2019.
Claims priority of provisional application 62/625,593, filed on Feb. 2, 2018.
Prior Publication US 2022/0175844 A1, Jun. 9, 2022
Int. Cl. A61K 35/30 (2015.01); A61K 38/18 (2006.01); A61P 27/06 (2006.01)
CPC A61K 35/30 (2013.01) [A61K 38/18 (2013.01); A61K 38/1825 (2013.01); A61K 38/1841 (2013.01); A61K 38/185 (2013.01); A61K 38/1866 (2013.01); A61P 27/06 (2018.01)] 17 Claims
 
1. A method of treating or preventing an optic nerve disease in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising one or more of:
(i) a population of optic nerve lamina region-neural progenitor cells (ONLR-NPCs),
(ii) ONLR-NPC conditioned media,
(iii) an ONLR-NPC lysate, and
thereby treating or preventing an optic nerve disease in the subject.